Avalyn Pharma (NASDAQ:AVLN) Upgraded by Zacks Research to Hold Rating

Avalyn Pharma (NASDAQ:AVLN) was upgraded by stock analysts at Zacks Research to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

A number of other equities research analysts have also weighed in on the stock. Evercore assumed coverage on shares of Avalyn Pharma in a report on Tuesday. They issued an “outperform” rating and a $51.00 price objective for the company. Jefferies Financial Group began coverage on shares of Avalyn Pharma in a research report on Monday. They issued a “buy” rating and a $52.00 target price on the stock. Guggenheim initiated coverage on shares of Avalyn Pharma in a research report on Monday. They set a “buy” rating and a $80.00 price target for the company. Morgan Stanley began coverage on Avalyn Pharma in a research note on Tuesday. They set an “overweight” rating and a $53.00 price objective on the stock. Finally, Wall Street Zen upgraded Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Avalyn Pharma currently has an average rating of “Buy” and an average target price of $59.00.

Avalyn Pharma Trading Up 5.9%

Shares of AVLN opened at $28.39 on Wednesday. Avalyn Pharma has a 1 year low of $25.05 and a 1 year high of $32.22.

Insider Buying and Selling

In other news, major shareholder Sr One Capital Management, Llc purchased 555,555 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was bought at an average cost of $18.00 per share, for a total transaction of $9,999,990.00. Following the acquisition, the insider directly owned 2,186,562 shares of the company’s stock, valued at $39,358,116. This represents a 34.06% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jill Carroll purchased 277,778 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were purchased at an average price of $18.00 per share, with a total value of $5,000,004.00. Following the completion of the acquisition, the director directly owned 2,186,562 shares in the company, valued at $39,358,116. The trade was a 14.55% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.